You are here: Industry Insights > Pharma in China

News List

Reverse Mergers Among Chinese Pharma Firms are Rising Xiaobin
January 23, 2025
Qilu Pharmaceutical applied for marketing of nusinersen injection, becoming the second in China. Nusinersen has a complex history due to high price. SMA treatment has multiple drugs and Chinese firms are making progress, with unmet needs remaining.
"Reverse Merger" Wave Rises: what's the Logic behind It? Yefenghong
January 23, 2025
Ikena Oncology and Inmagene signed a merger deal. The new firm focuses on IMG-007 for atopic dermatitis. Reverse mergers among Chinese pharma firms are rising.
China's Innovative Drugs Hunt for Billion Dollar Molecule Xiaobin
December 20, 2024
The Central Economic Work Conference in 2023 emphasized the need to promote industrial innovation through, especially by fostering new industries, new models, and new growth engines and developing new forms of productive forces.
Leading the Development of Bispecific ADCs, Multiple Chinese New Drugs Go Global Yi
December 20, 2024
On November 18, it was announced that VelaVigo has entered into a global strategic cooperation agreement with Avenzo Therapeutics.
New Pathways for Innovation and Transformation of Local Pharmaceutical Companies Xiaobin
December 20, 2024
INNOVATION announced it will acquire 100% equity in CSPC Baike for up to RMB 7.6 billion, 10% in cash and 90% in shares.
Established Pharmaceutical Company Makes a High-profile Entrance with "Unlimited" R&D Investment, Signaling an Imminent Explosion in This Emerging Field xiaobin
December 20, 2024
Recently, Northeast Pharm announced its plan to acquire a 70% stock equity in Dingcheng Taiyuan for a total cash consideration of approximately RMB 187 million, thereby obtaining controlling stake in the company.
Buyers and Sellers in the Weight Loss M&A Market：Without Buying and Selling, There's No Reshuffle Krebs Qin
December 20, 2024
The development of weight-loss drugs is currently one of the hottest topics in the pharmaceutical industry.
Universal CAR-T, Transaction +1 xiaobin
December 20, 2024
CAR-T therapy (chimeric antigen receptor t-cell immunotherapy) has been a favorite of the innovative drug market in recent years.
Popular APIs of the Year at Pharmasources.com PharmaSources
December 10, 2024
What are the APIs that caught the highest attention in the year at PharmaSources.com？
Has the Booming PD-1 Inhibitor Reached its Limit? Krebs Qin
October 18, 2024
In the field of oncology, Opdivo and Keytruda, as core immunotherapy agents for PD-1 inhibitors, have delivered significant survival benefits to patients with a variety of cancers.